Moon Kil Woong is currently a VP at a SME. Previously he was a tech stock consultant, VP of Research at ING, and sell side Director at Crédit Agricole Indosuez. Moon Kil Woong has a Masters in Public Administration from SJSU.
He contributes to both TalkMarkets and Seeking Alpha. You ...
more Moon Kil Woong is currently a VP at a SME. Previously he was a tech stock consultant, VP of Research at ING, and sell side Director at Crédit Agricole Indosuez. Moon Kil Woong has a Masters in Public Administration from SJSU.
He contributes to both TalkMarkets and Seeking Alpha. You can see his articles on TalkMarkets
here, and on Seeking Alpha
here.
less
Latest Comments
This Is How It’s Supposed To Work
Money needs to flow towards Covid treatments. As usual the US government is blowing billions financing the riskiest and most unlikely vaccine ideas that should take years in development and testing rather than treatments in the near term. They understandably want a giant feather in their cap and few will notice the garbage that lands on their hat instead making it obvious why the government should not be in the investment game.
Fundamentals Continue To Favor The Bulls
That is very true that fundamentals are bad post recession and that overall fundamentals are ok for stocks in general. Fear mongers are trying to scare away investors. The economy isn't that healthy, but big corporations are eating small company's lunches, especially if they are rolling with online ads which is buoying Google and Facebook.
This Is The Craziest Chart You'll See Today
The market is rewarding big companies at the cost of smaller ones. The S&P reflects that.
Are Stocks An Accurate Predictor Of Presidential Elections?
Stocks are not so much as economic growth is. The simple fact is that Trump is not looking good with the economy we have regardless of whether the stock market rises or not. It is like looking at a patient's temp after you dump them in cold water and saying they are ok now. Covid is his biggest problem and he has not dealt with it well yet.
HIV Cure Challenger CytoDyn Takes On Gilead Sciences
There is almost no institutional holding of this company. It should be positive for the stock given that it has been driven down on lies and short sellers profiting off of them. Long term holders are still waiting for clinical FDA trials to be released.
Dunkin Vs. Starbucks: Analyst Picks A Winner In A Socially Distanced World
The threat is people having no money to buy overpriced coffee in the morning and no commute to inspire lots of coffee drinking in the morning. No more stimulus will hurt both companies even more.
A Trade To Hedge A Top In Facebook With A Rebounding Google
Sadly people need to stop using it as they become a commodity to sell and sadly the most vulnerable get targeted by the most virulent like racists, gangs, cults, and terrorists.
HIV Cure Challenger CytoDyn Takes On Gilead Sciences
Uplisting news
talkmarkets.com/.../cytodyn-files-application-with-nasdaq-for-uplist
Is The Nasdaq 100’s Out-Performance Nearing A Top?
It certainly isn't sustainable. Indeed the economy favors the big companies over the small companies. This has been true for ages. What matters is what companies grow from here on out.
African Investments: A Look At Why Africa Is Adopting Cryptocurrencies
That's why scammers love this stuff.